Clinical Trial Update: A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

This is an update on a Phase 1/Phase 2 trial of AK104 plus lenvatinib in first-line advanced hepatocellular carcinoma. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Akeso | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED